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Abstract
• Celiac disease (CD) is a gluten-sensitivity enteropathy that occurs
in genetically susceptible individuals upon ingestion of gluten and
resolves when gluten is withdrawn from one’s diet.
• Serological markers play a major role in the diagnosis of celiac
disease, however a small intestinal biopsy is currently the gold
standard in symptomatic individuals.
• The purpose of this study was to determine if serological testing
alone is sufficient to confirm the diagnosis of CD and therefore
eliminate the need for a biopsy.
• The review of literature explored studies that compared small
intestinal biopsy with different serological testing in males and
females, <1 to 80 years in age, in order to determine if a biopsy
was always necessary.

Literature Review
• Gluten is a combination of proteins and found in certain grains,
such as wheat, rye and barley.
• It causes an immune-mediated response that can result in
disorders such as CD.
• CD causes mucosal damage leading to villous atrophy, crypt
hyperplasia, and infiltration of inflammatory cells.
• Proximal portion of the small intestine is most affected. Impaired
absorption and nutrient loss are a result of its inflammatory
effects.

Discussion
• Serologic testing of tissue transglutaminase antibodies has proven
to be effective at diagnosing celiac disease when values reach a
specific level and symptoms are supportive.
• This conclusion is further reinforced by the modified criteria
provided by the ESPGHAN.

Introduction
• Celiac disease (CD) is an autoimmune disorder of the
gastrointestinal tract that has increased in prevalence significantly
over the recent years.
• Occurs in genetically susceptible individuals upon ingestion of
gluten.
• Because gluten is the known trigger, the logical treatment option
would be to eliminate gluten from a person’s diet, also known as,
a gluten free diet (GFD).

Statement of the Problem
• If small bowel biopsies can be disregarded as a mandatory
diagnostic testing when specific serologic levels of
transglutaminase antibodies are reached, then patients can avoid
an invasive procedure and this will ultimately lead to a more rapid
diagnosis and earlier treatment.
.

Research Questions
• Can serologic testing alone be sufficient to confirm the diagnosis
of celiac disease in the symptomatic patient?
• In patients with celiac disease, what is the effect of a gluten-free
diet in reducing symptoms compared with no treatment?

http://wsm.wsu.edu/s/index.php?id=1031

• HLA-DQ2 and HLA-DQ8 (human leukocyte antigens) - key
players in the risk for CD in those genetically predisposed (HLADQ2 present in 95% of patients diagnosed)
• Environmental factors: Early exposure and overexposure to
gluten, early infection with intestinal viruses, and changes in
bacterial flora of the gut
• Its diagnosis is based on abnormal small intestinal histopathological findings determined by endoscopic biopsy followed
by a clinical response to a strict gluten free diet
• Serologic testing is initial step in screening CD and the antibodies
present include: IgA-tissue transglutaminase antibodies (IgAtTGA), anti-gliadin antibodies, IgA-endomysial antibodies (IgAEMA), deamidated gliadin antibodies.
• The search of literature provided the following study results:
– Mubarak et al., 2012, found that in patients with levels of IgAtTGA > or equal to 100 U/mL, with improved symptoms
following a gluten free diet, these patients had histological
lesions compatible with CD.
– Wakim-Fleming et al., 2013, found that symptomatic patients
whose tTGA levels were > 118 U and who responded to a
GFD, did not necessarily warrant a small intestinal biopsy.
– Husby et al., 2012, provided the new guidelines published in
ESPGHAN for the diagnostic criteria for CD: If the IgA-tTG
titers are >10 times the upper limit of normal, then the option is
to diagnose CD without small bowel biopsies. Strict protocol is
to be applied including confirmation of diagnosis by an
antibody decline and a clinical response to a gluten free diet.
– Norstrom et al., 2012, found that all symptoms improved as
well as significant declines in tissue transglutaminase antibody
levels while adhering to a GFD.

• The data does however still support the need for small intestinal
biopsy in more complex patients.
• In addition to ESPGHAN’s modifications to the diagnostic
criteria, additional research has concluded that a gluten free diet is
the current effective treatment option to alleviate the effects of
this enteropathic disease.

Applicability to Clinical
Practice
• Diagnosis relies heavily on practitioner suspicion.
• Recent changes in the diagnostic criteria have created a potential
for making a diagnosis by the healthcare provider sooner in the
disease’s development, allowing for less damage by the disease to
the intestinal villi.
• Serological testing is a less invasive, less expensive approach in
initiating a diagnosis.
• Key elements that need to be introduced to the patient in order to
manage their disease effectively:
Consultation with a skilled dietitian
Education about the disease
Lifelong adherence to a GFD
Identify and treat nutritional deficiencies
Access to an advocacy group
Continuous f/u by a multidisciplinary team
• Health care providers are given the opportunity to screen their
symptomatic patients with a high degree of specificity using
serological testing. Not all, but a vast majority of patients will be
able to initiate treatment earlier without the need for a small
intestinal biopsy.
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